Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This multicenter, prospective, cohort study enrolled patients with metastatic
hormone-sensitive prostate cancer who had been treated with other novel endocrine or systemic
regimens (excluding patients treated with pre-order chemotherapy alone or bicalutamide); To
observe the efficacy and safety of rezvilutamide alone or in combination with abiraterone in
hormone-sensitive prostate cancer patients with PSA progression following prior sequence
therapy.